High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

• Main Authors: Mario Karolyi (Author), Sara Omid (Author), Erich Pawelka (Author), Bernd Jilma (Author), Thomas Stimpfl (Author), Christian Schoergenhofer (Author), Hermann Laferl (Author), Tamara Seitz (Author), Marianna Traugott (Author), Christoph Wenisch (Author), Alexander Zoufaly (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods: COVID-19 positive patients admitted to the ho...